Delving into the Latest Updates on Shanghai EA therapeutics with Synapse

Overview

Tags

Other Diseases

Eye Diseases

Nervous System Diseases

Monoclonal antibody

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	2
Hemic and Lymphatic Diseases	2
Immune System Diseases	2
Infectious Diseases	2
Endocrinology and Metabolic Disease	2
Neoplasms	1

Top 5 Drug Type	Count

Biological products	5
Monoclonal antibody	1

Top 5 Target	Count

Complement system proteins	3
TSHR(Thyroid stimulating hormone receptor)	1
C5(Complement C5)	1

[Translation] This is a dose-escalation, open-label, multicenter Phase I clinical trial evaluating the safety, tolerability, preliminary efficacy, pharmacodynamics, and pharmacokinetics of EA5 injection in adult participants with antiphospholipid syndrome (APS) and recurrent thrombosis under the established criteria of treatment.

主要目的：评价在标准治疗背景下，EA5 注射液治疗APS 伴复发性血栓成年试验参与者的安全性和耐受性。次要目的：评价EA5 注射液治疗APS 伴复发性血栓成年试验参与者的初步疗效。评估EA5 注射液的免疫原性。评估EA5 注射液的药代动力学特征。评估EA5 注射液对末端补体活性的抑制作用。探讨EA5 注射液治疗APS 的生物标志物变化（如D-二聚体、凝血酶-抗凝血酶复合物（TAT））。探索性目的：进一步评估EA5 注射液对APS 的生物标志物影响【超敏C 反应蛋白（hs-CRP）、血管细胞粘附分子（VCAM-1）】。

[Translation]

Primary Objective: To evaluate the safety and tolerability of EA5 injection in adult participants with APS and recurrent thrombosis under standard treatment. Secondary Objectives: To evaluate the preliminary efficacy of EA5 injection in adult participants with APS and recurrent thrombosis. To assess the immunogenicity of EA5 injection. To assess the pharmacokinetic characteristics of EA5 injection. To assess the inhibitory effect of EA5 injection on terminal complement activity. To investigate changes in biomarkers (e.g., D-dimer, thrombin-antithrombin complex (TAT)) in APS treatment. Exploratory Objectives: To further evaluate the effects of EA5 injection on biomarkers of APS [high-sensitivity C-reactive protein (hs-CRP), vascular cell adhesion molecule (VCAM-1)].

Start Date-

Sponsor / Collaborator

Shanghai EA therapeutics

[+1]

100 Clinical Results associated with Shanghai EA therapeutics

Login to view more data

0 Patents (Medical) associated with Shanghai EA therapeutics

Login to view more data

100 Deals associated with Shanghai EA therapeutics

Login to view more data

100 Translational Medicine associated with Shanghai EA therapeutics

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

4

Preclinical

Phase 1

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

EA5 ( Complement system proteins )	Antiphospholipid Syndrome More	IND Approval
EA501 ( Complement system proteins )	Hemoglobinuria, Paroxysmal More	Preclinical
EA502 ( Complement system proteins )	Diabetic macular oedema More	Preclinical
EA7	Virus Diseases More	Preclinical
CN116712390 ( C5 )Patent Mining	Nervous System Diseases More	Discovery